• Safety Information
  • Prescribing Information
  • Patient Prescribing Information

Reimbursement and Support

Patient Assistance
Patient Education Materials
Online Patient Resources

Patient Assistance

"PatientOne" is the Lilly Oncology program that addresses financial, access, and claim issues for patients who are candidates for Lilly Oncology products.

  • Anticipating the needs of the patient

  • Information that drives successful claims

  • Complete ownership of tasks your patient needs

PatientOne provides services in a way that can make a difference. Filling one need at a time. Personally.

Among many other services, you can count on:

  • Reliable, individualized treatment support

  • Patient assistance

  • Insurance verification

  • Claim submission assistance

  • Information

  • Payment methodologies and allowables

  • Drug information and coding

  • Claim appeals

  • A full, start-to-finish commitment

Patients we can help:

Call 1-866-4PatOne (1-866-472-8663) and let us know what you need. Live specialists are available Monday through Friday, 9 am to 7 pm EST.

Back to Top

Patient Education Materials

The educational materials available here for download can help you better understand cancer treatment with ALIMTA.

ALIMTA Patient Therapy Guide: Your First-Line Treatment with ALIMTA - Advanced Nonsquamous NSCLC

ALIMTA Patient Therapy Guide: Your Treatment with ALIMTA After Prior Chemotherapy - Advanced Nonsquamous NSCLC

ALIMTA Patient Therapy Guide: Your Treatment with ALIMTA - Malignant Pleural Mesothelioma

Online Patient Resources

There are a number of cancer resources available on the Internet for patients. The following links are provided for their assistance. Note that these resources are independent from Eli Lilly and Company; Lilly does not control the content.

All types of cancer
Lung cancer
Malignant pleural mesothelioma

All types of cancer

Back to Top

Lung cancer

Back to Top

Malignant pleural mesothelioma

  • Mesothelioma Applied Research Foundation
    1-877-END-MESO
    (1-877-363-6376)
    www.marf.org

Back to Top

Important Safety Information for ALIMTA (pemetrexed for injection)

ALIMTA is approved by the FDA in combination with cisplatin (another chemotherapy drug) for the initial treatment of advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.

ALIMTA as a single agent (used alone) is approved for maintaining the initial treatment effect of chemotherapy in patients with advanced nonsquamous non-small cell lung cancer whose disease has not worsened after initial therapy. ALIMTA is not indicated for patients who have another type of non-small cell lung cancer called squamous cell.

ALIMTA is approved by the FDA as a single agent (used alone) for the treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC, after prior chemotherapy. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.

ALIMTA is a treatment for malignant pleural mesothelioma (MPM), which is a cancer that affects the inside lining of the chest cavity. ALIMTA is given with cisplatin, another anticancer medicine (chemotherapy), when surgery is not an option.

ALIMTA may not be appropriate for some patients. If you are allergic to ALIMTA, tell your doctor because you should not receive it. If you think you are pregnant, are planning to become pregnant, or are nursing, please tell your healthcare team. ALIMTA may harm your unborn or nursing baby. Your physician may advise you to use effective contraception (birth control) to prevent pregnancy while you are being treated with ALIMTA.

If you have liver or kidney problems, be sure to tell your doctor. Your dose of ALIMTA may have to be changed, or ALIMTA may not be right for you. There is a risk of side effects associated with ALIMTA therapy. ALIMTA can suppress bone marrow function. It is very important to take folic acid and vitamin B12 prior to and during your treatment with ALIMTA to lower your chances of harmful side effects.

Your healthcare professional will prescribe a medicine called a corticosteroid, which lowers your chances of getting skin reactions with ALIMTA. Ask your healthcare professional before taking medicines called NSAIDs (nonsteroidal anti-inflammatory drugs used to treat pain or swelling). Tell your doctor if you are taking other medicines, including prescription and non-prescription medicines, vitamins, and herbal supplements.

The most common side effects of ALIMTA when given alone or in combination with cisplatin, another chemotherapy drug, are low blood cell counts (red blood cells, white blood cells, and platelets); tiredness; stomach upset, including nausea, vomiting, and diarrhea; mouth, throat, or lip sores; loss of appetite; rash; and constipation.

Call your healthcare professional right away if you have a fever, chills, diarrhea, or mouth sores. These symptoms could mean you have an infection. These are not all of the side effects of ALIMTA. If you have any side effect that bothers you or that doesn't go away, be sure to talk with your healthcare professional.

You will have regular blood tests before and during your treatment with ALIMTA. Your doctor may adjust your dose of ALIMTA or delay your treatment based on the results of your blood test and on your general condition.

For more information about all of the side effects of ALIMTA, please talk with your healthcare team, see the Patient Prescribing Information and full Prescribing Information, or call 1-800-545-5979.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

SG24